3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neuroblastoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Pemetrexed
5
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cisplatin
4
fludarabine
3
Cyclophosphamide
3
Radiotherapy, Intensity-Modulated
2
Cerebral Decortication
2
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
avelumab
1
atezolizumab
1
Platinum
1
Influenza Vaccines
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Blood Component Removal
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Influenza Vaccines
×
90 days
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled